$Hims & Hers Health (HIMS.US)$ shares are 11% trading lower Thursday. The U.S. Food and Drug Administration issued a new decision about tirzepatide injection shortages. Here's what you need to know.
What To Know: The FDA announced today that the shortage of tirzepatide injections, a GLP-1 medication, has been resolved. The shortage began in 2022 due to high demand and has ended as manufacturing capacity and product availability are sufficient to meet national demand. However, the FDA warned of potential localized supply chain disruptions as products are distributed to pharmacies.
To avoid interruptions in treatment, the FDA is allowing compounders using tirzepatide to continue their activities temporarily. State-licensed pharmacies have until February 18, 2025, and outsourcing facilities until March 19, 2025, to comply with this grace period.
Meanwhile, other GLP-1 drugs, including dulaglutide, semaglutide and liraglutide, remain in shortage. Despite some reports of product availability, the FDA has not yet resolved these shortages and is actively monitoring the situation.
This announcement follows the FDA's October 2024 decision that determined that the tirzepatide shortage was over. However, this was reevaluated after legal challenges. This updated decision confirms that the shortage is resolved.
The news may influence investor sentiment, given the role of GLP-1 drugs in weight loss and diabetes treatment. Ongoing shortages of similar medications and regulatory updates could continue to affect market perspectives.
Hims & Hers Health, Inc. (NYSE:HIMS)は、木曜日に取引が低下しています。アメリカ食品医薬品局は、チルゼパチド注射の不足に関する新たな決定を発表しました。知っておくべきことは以下の通りです。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
Meanwhile, other GLP-1 drugs, including dulaglutide, semaglutide and liraglutide, remain in shortage. Despite some reports of product availability, the FDA has not yet resolved these shortages and is actively monitoring the situation.
一方、ダラグルチド、セマグルチド、リラグルチドなどのその他のGLP-1薬は、引き続き不足しています。一部の製品供給の報告があるものの、FDAはこれらの不足をまだ解決しておらず、状況を積極的に監視しています。
